Find Funding Opportunities

Purpose: The goal of this initiative is to create a center (or centers) to 1) evaluate new monoclonal antibodies (mABs) to neurodevelopmental antigens using multiple model systems and 2) provide detailed information for use of these reagents to the research community. Some of the most powerful tools in understanding nervous system development are antibodies that monitor the expression of key developmental proteins. Accordingly, one of the most compelling needs within the community is greater access to well-validated mABs. As an initial step to address this need, the NIH Blueprint for Neuroscience Research (subsequently referred to as the Blueprint) is currently funding the targeted creation and distribution of a large number of high quality monoclonal antibodies via the Blueprint Resource Antibodies Initiative for Neurodevelopment (BRAINdev) in partnership with the UC Davis/NINDS/NIMH NeuroMab Facility (www.neuromab.org). An important component of the overall Blueprint mAB plan is to provide detailed information on the performance of the antibodies across model systems common to neurodevelopmental research. While BRAINdev antibodies will initially be assayed in a limited number of model organisms via NeuroMab, their utility in a broad range model systems will be evaluated by a associated, but distinct center(s) to be called the Center(s) for Neurodevelopmental Antibodies (CENA). All of the BRAINdev antibodies, and all of the evaluation data produced by the centers, will be made available to the research community. To fulfill the evaluation portion of this plan, this Funding Opportunity Announcement (FOA) solicits applications directed toward the creation of a center (or centers) to perform further examination of mABs immunoreactivity in the developing central and peripheral nervous systems of multiple model systems. This announcement specifically requests the creation of antibody evaluation centers which will, in total, determine the ability of antibodies to recognize their corresponding antigen during development in the following organisms: fruit fly (D. melanogaster), nematode (C. elegans), zebrafish (D. rerio), mouse (M. musculus), chick (G. gallus), frog (X. laevis and X. tropicalis), rat (R. norvegicus), rhesus monkey (M. mulatta) and human (H. sapiens). Individual centers will establish experimental conditions for antibody use during development, including immunoblotting, and immunohistochemistry in at least five species, as well as provide these data to the neurodevelopment community. Mechanism of Support. This FOA uses the Resource-Related Research Projects-Cooperative Agreement (U24) award mechanism Funds Available and Anticipated Number of Awards. The Blueprint is a framework to enhance cooperative activities among the NIH Office of the Director and 15 NIH Institutes and Centers (ICs) that support research on the central and peripheral nervous systems. In fiscal year 2008, the Blueprint is emphasizing neural development. The participating Blueprint organizations intend to commit $1,200,000 over a two-year period to fund 1 to 3 applications in response to this FOA. Additional meritorious applications may be funded by individual NIH Institutes. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $600,000 per year for a two-year period. Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organization; Eligible agencies of the Federal government. Eligible Project Directors/Principal Investigators (PDs/PIs): Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct. Renewals and Resubmissions. Neither renewals or resubmissions will be accepted for this FOA. Number of PDs/PIs. More than one PD/PI, or multiple PDs/PIs, may be designated on the application.  Application Materials. See Section IV.1 for application materials. Hearing Impaired. Telecommunications for the hearing impaired is available at: TTY 301-451-0088. Initial merit review will be convened by NINDS Special Receipt Date: February 15, 2008

-Purpose. This Agency-wide Funding Opportunity Announcement (FOA) is a Program Announcement (PA) to encourage new research applications proposing research on hPSCs from non-embryonic sources. This FOA addresses Executive Order 13435 issued by President George W. Bush on June 20, 2007.The Executive Order requires that The Secretary of Health and Human Services shall conduct and support research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for diseases and other adverse health conditions, but are derived without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-08-044, that encourages applications under the NIH Exploratory/Developmental (R21) grant award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

-Purpose. This Agency-wide Funding Opportunity Announcement (FOA) is a Program Announcement (PA) to encourage new research applications proposing research on hPSCs from non-embryonic sources. This FOA addresses Executive Order 13435 issued by President George W. Bush on June 20, 2007.The Executive Order requires that The Secretary of Health and Human Services shall conduct and support research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for diseases and other adverse health conditions, but are derived without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo. -Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-08-043, that encourages applications under the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

-Purpose. This FOA invites applications for projects that will examine, through molecular approaches, the relationship between changes in the human microbiome and human health and disease. This program is a component of the NIH Roadmap 1.5 Human Microbiome Project (http://nihroadmap.nih.gov/hmp/).  -Mechanism of Support. This FOA will use the UH2/UH3 cooperative agreement mechanisms to support the demonstration project awards. The program will be funded in two phases, as allowed by this mechanism. The initial one-year pilot phase (UH2) will allow investigators to procure samples and generate data that will be used to support the scale-up phase (UH3), which will be awarded after administrative review to those projects that have the most promise to demonstrate whether or not the human microbiome plays an important role in human health and disease.  -Funds Available and Anticipated Number of Awards. The total amount of funds available for these awards is approximately $4 million total costs for the UH2 in FY 09 and $24.3 million for the UH3 in FY 10-12. Up to 10 UH2 and 5 UH3 awards are anticipated from this solicitation. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

The National Institute of Neurological Disorders and Stroke (NINDS) and the Canadian Stroke Network (CSN) have developed a partnership to facilitate the development of multi-institutional, multidisciplinary collaborations to address the pre-clinical translational challenges in stroke research and to conduct pre-clinical trials. Applications must have a consortium structure comprised of at least 3 participating laboratories at different institutions and a coordinating center that is responsible for data coordination, site and steering committee communication. Each preclinical site should have two (2) stroke models (species) available with one model common to all sites within the consortium. A steering committee of external advisors, NIH staff and consortium investigators will be responsible for protocol development. The NINDS intends to commit approximately $1.5 million in total costs in FY 2008 for this announcement to support a total of 2 meritorious applications. A consortium may request a project period of up to four years and a budget for direct costs up to $500,000 in each year. The CSN is currently funding one Canadian consortium at the level of $1.10 million per year for a 2 year period with the opportunity to extend for an additional 2 year period. This funding opportunity will use the NIH cooperative agreement research grant (U01) award mechanism. Eligible organizations include Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organization; Eligible agencies of the Federal government; Faith-based or community based organizations.  Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Applicants may submit more than one application, provided they are scientifically distinct. Competing renewal (formerly “competing continuation”) and resubmission applications will not be accepted under this FOA. At this time, it is not known if this FOA will be reissued. More than one PD/PI, or multiple PDs/PIs, may be designated on the application.

-Purpose. This FOA provides updated guidelines for the National Institute of General Medical Sciences (NIGMS) Minority Biomedical Research Support (MBRS) Support of Competitive Research (SCORE) Program SC1 mechanism for Research Advancement Awards. -Mechanism of Support. The SCORE Program is a developmental program designed to increase the research competitiveness of faculty at minority-serving institutions (MSIs) and the institutions faculty research capabilities. To better achieve these objectives, three funding opportunities exist for individual investigator-initiated research awards according to their developmental level. The mechanisms used for these funding opportunities are the SC1 (PAR-08-026), SC2 (PAR-08-027) and SC3 (PAR-08-028) awards for individual investigators. Descriptions of the SC2 andSC3 mechanisms may be found at the NIGMS website, http://www.nigms.nih.gov/Minority/MBRS/. This announcement for the SC1 award outlines the investigator-initiated research project for faculty who are at the most advanced formative stages of their research career, i.e., who are engaged in state-of-the-art biomedical or behavioral research and are productive as evidenced by a steady track record of peer-reviewed publications, yet they have not had significant non-SCORE support and are planning to transition to other major external sources of support. It is the expectation of this award that by providing support to conduct competitive research and requiring participation of SC1 Principal Investigators (PI) in grantsmanship workshops and biennial PI meetings, they will be successful in securing non-SCORE external support.

This Funding Opportunity Announcement (FOA) issued by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), and National Library of Medicine (NLM) solicits Research Project Grant (R01) applications from institutions/ organizations that propose to develop predictive multiscale models of the physiome in health and disease.

-The Organ Systems Branch of the Office of Centers, Training, and Resources, Office of the Director, National Cancer Institute, invites grant applications for Specialized Programs of Research Excellence (SPOREs) in organ-specific cancers.This Funding Opportunity Announcement (FOA) targets applicant institutions with demonstrated ability to conduct translational research in the prevention, etiology, screening, diagnosis, and/or treatment of human cancer.Applications may address cancer in any organ site, but each application must be organ site specific.Examples of organ sites include (but are not limited to) leukemias, lymphomas, myelomas, brain, breast, gastrointestinal (GI) system, genitourinary (GU) system, gynecologic (GYN) system, head & neck, lung, ovary, pancreas, prostate, skin, oral cavity & pharynx, bones, joints, soft tissue, eye & orbit, and endocrine system.Applicants are encouraged to consult with the NCI program staff members regarding the choice of cancer organ site.Translational research, as defined by the NCI, uses knowledge of human biology to develop and test the feasibility of cancer-relevant interventions in humans and/or determines the biological basis for observations made in individuals with cancer or in populations at risk for cancer. -Required components of a SPORE grant application include a minimum of four translational research projects, one or more cores, and developmental research and career development programs.A required core in a SPORE is a human cancer tissue core for the particular organ site that will benefit translational research. -SPOREs are designed to foster extended collaborations in critical areas of research among laboratory and clinical or applied scientists.Every SPORE is expected to have a robust research base in the respective cancer type, good access to patient populations, and substantial commitment from the applicant institution.Inter-SPORE collaborations and collaborations between SPOREs and other NIH programs are strongly encouraged.Each SPORE and the "network" of SPOREs are expected to conduct research that will have the most immediate impact possible on reducing incidence and mortality of human cancer.

-Purpose. This Funding Opportunity Announcement (FOA) is a program announcement (PA) issued by the National Institute of Neurological Disorders and Stroke (NINDS), the National Eye Institute (NEI), the National Institute on Aging (NIA), the National Cancer Institute (NCI), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH). The aim of this FOA is to invite applications to study angiogenesis in the nervous system.Specific areas of research this FOA seeks to encourage include study of the mechanisms controlling angiogenic responses to physiological and pathological stimuli, the development and patterning of nervous system vasculature, and the etiology of disorders affecting development and/or ongoing angiogenesis in nervous system vasculature. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-08-016, that encourages applications under the NIH Exploratory/Developmental (R21) grant award mechanism. Please note that NIDDK is not participating in the companion R21 FOA. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications

-Purpose. This Funding Opportunity Announcement (FOA) is a program announcement (PA) issued by the National Institute of Neurological Disorders and Stroke (NINDS), the National Eye Institute (NEI), the National Institute on Aging (NIA), the National Cancer Institute (NCI), and the National Institute of Mental Health (NIMH), National Institutes of Health (NIH). The aim of this FOA is to invite applications to study angiogenesis in the nervous system.Specific areas of research this FOA seeks to encourage include study of the mechanisms controlling angiogenic responses to physiological and pathological stimuli, the development and patterning of nervous system vasculature, and the etiology of disorders affecting development and/or ongoing angiogenesis in nervous system vasculature. -Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-08-015, that encourages applications under the NIH Research Project Grant (R01) award mechanism. Please note that NIMH is not participating in the companion R01 FOA. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.